247 related articles for article (PubMed ID: 20028747)
61. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
62. Deguelin as a chemopreventive agent in mouse lung tumorigenesis induced by tobacco smoke carcinogens.
Hecht SS
J Natl Cancer Inst; 2005 Nov; 97(22):1634-5. PubMed ID: 16288111
[No Abstract] [Full Text] [Related]
63. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
De Angel RE; Conti CJ; Wheatley KE; Brenner AJ; Otto G; Degraffenried LA; Hursting SD
Mol Carcinog; 2013 Jun; 52(6):446-58. PubMed ID: 22290600
[TBL] [Abstract][Full Text] [Related]
64. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
65. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Mallon R; Hollander I; Feldberg L; Lucas J; Soloveva V; Venkatesan A; Dehnhardt C; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Gibbons J
Mol Cancer Ther; 2010 Apr; 9(4):976-84. PubMed ID: 20371716
[TBL] [Abstract][Full Text] [Related]
66. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
67. Ultrasound induces hypoxia-inducible factor-1 activation and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of rapamycin pathway in osteoblasts.
Tang CH; Lu DY; Tan TW; Fu WM; Yang RS
J Biol Chem; 2007 Aug; 282(35):25406-15. PubMed ID: 17588951
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
69. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
70. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
71. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
72. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.
Legrier ME; Yang CP; Yan HG; Lopez-Barcons L; Keller SM; Pérez-Soler R; Horwitz SB; McDaid HM
Cancer Res; 2007 Dec; 67(23):11300-8. PubMed ID: 18056456
[TBL] [Abstract][Full Text] [Related]
73. 5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
Kim KM; Heo DR; Lee J; Park JS; Baek MG; Yi JM; Kim H; Bang OS
Chem Biol Interact; 2015 Jan; 225():32-9. PubMed ID: 25446852
[TBL] [Abstract][Full Text] [Related]
74. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.
Sato T; Nakashima A; Guo L; Coffman K; Tamanoi F
Oncogene; 2010 May; 29(18):2746-52. PubMed ID: 20190810
[TBL] [Abstract][Full Text] [Related]
75. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
[TBL] [Abstract][Full Text] [Related]
76. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
77. Serine Protease from
Chen Y; Tang Y; Tang Y; Yang Z; Ding G
Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31226829
[TBL] [Abstract][Full Text] [Related]
78. AKT and the phosphatidylinositol 3-kinase/AKT pathway: important molecular targets for lung cancer prevention and treatment.
Crowell JA; Steele VE
J Natl Cancer Inst; 2003 Feb; 95(4):252-3. PubMed ID: 12591974
[No Abstract] [Full Text] [Related]
79. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
80. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
